Rockefeller Financial Services’s Alnylam Pharmaceuticals ALNY Stock Holding History

Rockefeller Financial Services’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	$31.4M	Sell	246,931 -76,433	-24%	-$9.6M	0.5%	55
2017 Q3	$38M	Sell	323,364 -8,694	-3%	-$742K	0.72%	42
2017 Q2	$26.5M	Sell	332,058 -174,165	-34%	-$11.1M	0.53%	50
2017 Q1	$25.9M	Buy	506,223 +495,730	+4,724%	+$22.9M	0.52%	49
2016 Q4	$393K	Buy	10,493 +8,591	+452%	+$360K	0.01%	271
2016 Q3	$129K	Sell	1,902 -3,400	-64%	-$240K	﹤0.01%	330
2016 Q2	$294K	Hold	5,302	–	–	0.01%	298
2016 Q1	$333K	Hold	5,302	–	–	0.01%	287
2015 Q4	$499K	Buy	5,302 +446	+9%	+$41.4K	0.01%	254
2015 Q3	$390K	Buy	+4,856	New	+$540K	0.01%	273

Other funds holding ALNY

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

BRC

Blue Ridge Capital New York $215M AUM

Rockefeller Financial Services's ALNY Position: Q4 2017 in Review

Rockefeller Financial Services reduced its Alnylam Pharmaceuticals (ALNY) stake by 24% in Q4 2017, selling an estimated $9.6M and leaving 246,931 shares worth $31.4M. The position accounts for 0.5% of the portfolio, ranked #55.

Rockefeller Financial Services first reported a position in ALNY in Q3 2015 and has held it in 10 quarters since. The position peaked at $38M in Q3 2017. 282 funds tracked by Wall St. Rank hold ALNY as of Q4 2017.

Rockefeller Financial Services held 246,931 shares of Alnylam Pharmaceuticals worth $31.4M as of Q4 2017.
Rockefeller Financial Services sold 76,433 Alnylam Pharmaceuticals shares in Q4 2017, an estimated $9.6M.
Alnylam Pharmaceuticals made up 0.5% of Rockefeller Financial Services's portfolio in Q4 2017, its #55 holding.
Rockefeller Financial Services first reported a position in Alnylam Pharmaceuticals in Q3 2015 and has held it in 10 quarters since.
Rockefeller Financial Services's Alnylam Pharmaceuticals position peaked at $38M in Q3 2017.
282 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q4 2017.

Based on Rockefeller Financial Services's 13F filing for Q4 2017, filed 2 Feb 2018.